Patents by Inventor Hans-Jurgen E. Hess

Hans-Jurgen E. Hess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dimethyl 2-oxo-6-cyanohexyl-phosphonate
    Patent number: 4078021
    Abstract: The 19-cyano-20-nor derivatives of prostaglandins E.sub.1 and E.sub.2, and certain esters thereof, are bronchodilatory agents, useful in the treatment of bronchial asthma, bronchitis, pneumonia and emphysema. The 19-cyano-20-nor derivatives of prostaglandins E.sub.1 and E.sub.2, and certain esters thereof, which also have protecting groups on the hydroxy groups at C-11 and C-15 are useful intermediates for the preparation of the bronchodilatory agents of this invention.
    Type: Grant
    Filed: April 25, 1977
    Date of Patent: March 7, 1978
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Thomas K. Schaaf
  • Cyanoprostaglandins
    Patent number: 4074044
    Abstract: The 19-cyano-20-nor derivatives of prostaglandins E.sub.1 and E.sub.2, and certain esters thereof, are bronchodilatory agents, useful in the treatment of bronchial asthma, bronchitis, pneumonia and emphysema. The 19-cyano-20-nor derivatives of prostaglandins E.sub.1 and E.sub.2, and certain esters thereof, which also have protecting groups on the hydroxy groups at C-11 and C-15 are useful intermediates for the preparation of the bronchodilatory agents of this invention.
    Type: Grant
    Filed: April 25, 1977
    Date of Patent: February 14, 1978
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Thomas K. Schaaf
  • Cyanoprostaglandins
    Patent number: 4045465
    Abstract: The 19-cyano-20-nor derivatives of prostaglandins E.sub.1 and E.sub.2, and certain esters thereof, are bronchodilatory agents, useful in the treatment of bronchial asthma, bronchitis, pneumonia and emphysema. The 19-cyano-20-nor derivatives of prostaglandins E.sub.1 and E.sub.2, and certain esters thereof, which also have protecting groups on the hydroxy groups at C-11 and C-15 are useful intermediates for the preparations of the bronchodilatory agents of this invention.
    Type: Grant
    Filed: August 6, 1976
    Date of Patent: August 30, 1977
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Thomas K. Schaaf
  • Fused pyrimidin-4(3H)-ones as antiallergy agents
    Patent number: 4044134
    Abstract: Fused heterocyclic ring systems in which a quinoline or a pyridine component is "fused" to a pyrimidine having a 2-methyl, 2-ethyl, or 2-acetyl group and a 4-keto group, and to similar ring systems in which a quinoline, a naphthalene or a pyridine component is fused to a pyrimidine having a 2-carboxy group and a 4-keto group, derivatives, and pharmaceutically-acceptable cationic salts thereof, and their use as antiallergy agents, and intermediates therefor.
    Type: Grant
    Filed: March 16, 1976
    Date of Patent: August 23, 1977
    Assignee: Pfizer Inc.
    Inventors: Thomas H. Althuis, Leonard J. Czuba, Hans-Jurgen E. Hess, Saul B. Kadin
  • 15-Substituted-.omega.-pentanorprostaglandins
    Patent number: 4036832
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: July 15, 1976
    Date of Patent: July 19, 1977
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • Magnesium salts of 2-descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-omega-pentanopro staglandins
    Patent number: 4035360
    Abstract: The magnesium salts of 2-descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorpr ostaglandins are disclosed. The novel prostaglandin salt of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action and are further valuable because they are crystalline and thus may be easily isolated, purified and compounded into medicaments.
    Type: Grant
    Filed: December 22, 1975
    Date of Patent: July 12, 1977
    Assignee: Pfizer Inc.
    Inventors: Michael R. Johnson, Thomas K. Schaaf, Jasjit S. Bindra, Hans-Jurgen E. Hess, James F. Eggler
  • 13,14-Dihydro-15-substituted-.omega.-pentanorprostaglandins of the two series
    Patent number: 4011262
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: July 3, 1974
    Date of Patent: March 8, 1977
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • 11-Desoxy-16-aryl-.omega.-tetranorprostaglandins
    Patent number: 3984400
    Abstract: 11-Desoxy-16-aryl-.omega.-tetranorprostaglandins and various intermediates and processes employed in their preparation are disclosed. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins but they exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: October 21, 1975
    Date of Patent: October 5, 1976
    Assignee: Pfizer Inc.
    Inventors: James F. Eggler, Jasjit S. Bindra, Hans-Jurgen E. Hess
  • 15-Substitute D-.omega.-pentanorprostaglandins
    Patent number: 3980642
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: November 19, 1975
    Date of Patent: September 14, 1976
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • Fused pyrimidin-4(3H)-ones as antiallergy agents
    Patent number: 3974161
    Abstract: Fused heterocyclic ring systems in which a quinoline or a pyridine component is "fused" to a pyrimidine having a 2-methyl, 2-ethyl, or 2-acetyl group and a 4-keto group, and to similar ring systems in which a quinoline, a naphthalene or a pyridine component is "fused" to a pyrimidine having a 2-carboxy group and a 4-keto group, derivatives, and pharmaceutically-acceptable cationic salts thereof, and their use as antiallergy agents, and intermediates therefor.
    Type: Grant
    Filed: July 5, 1974
    Date of Patent: August 10, 1976
    Assignee: Pfizer Inc.
    Inventors: Thomas H. Althuis, Leonard J. Czuba, Hans-Jurgen E. Hess, Saul B. Kadin
  • 13,14-Dihydro-15-substituted-.omega.-pentanorprostaglandins
    Patent number: 3974213
    Abstract: The 15 aryl substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: July 3, 1974
    Date of Patent: August 10, 1976
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • 15-Substituted-.omega.-pentanorprostaglandins
    Patent number: 3971826
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: July 3, 1974
    Date of Patent: July 27, 1976
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • Piperazino quinazoline bronchodilators
    Patent number: 3966936
    Abstract: A series of novel 4-piperazino-6,7-dialkoxyquinazolines and 1-piperazino-6,7-dialkoxyisoquinolines have been prepared, including their acid addition salts. These compounds are useful in therapy as bronchodilators and as smooth muscle relaxants. Methods for their preparation from known compounds are provided.
    Type: Grant
    Filed: May 29, 1975
    Date of Patent: June 29, 1976
    Assignee: Pfizer Inc.
    Inventors: Timothy H. Cronin, Hans-Jurgen E. Hess
  • Heterocyclic 15-substituted-.omega.-pentanorprostoglandins
    Patent number: 3956284
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: July 3, 1974
    Date of Patent: May 11, 1976
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • N-substituted prostaglandin carboxamides
    Patent number: 3954741
    Abstract: The N-substituted prostaglandin carboxamides and various intermediates employed in their preparation. Such prostaglandin analogs exhibit the same activity profiles as the corresponding natural prostaglandin but with increased duration of action and increased selectivity of action.
    Type: Grant
    Filed: May 30, 1973
    Date of Patent: May 4, 1976
    Assignee: Pfizer Inc.
    Inventors: Thomas K. Schaaf, Leonard J. Czuba, Hans-Jurgen E. Hess
  • 4(Tetrazol-5-yl)-butyltriphenylphosphonium halide compounds
    Patent number: 3953466
    Abstract: 4(Tetrazol-5-yl)-butyltriphenylphosphonium compounds are disclosed which are useful for preparing tetrazoyl derivatives of naturally occurring prostaglandins.
    Type: Grant
    Filed: July 25, 1974
    Date of Patent: April 27, 1976
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Leonard J. Czuba, Thomas K. Schaaf
  • Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives
    Patent number: 3935213
    Abstract: 6,7-Dimethoxy-4-amino-2-(4-substituted piperazin-1-yl)-quinazolines and 6,7,8-trimethoxy-4-amino-2-(4-substituted piperazin-1-yl)quinazolines are produced by either: (1) reaction of the appropriate 4,5-dimethoxy substituted or 3,4,5-trimethoxy substituted 2-aminobenzonitrile with certain 1,4-disubstituted piperazines; or (2) reaction of the appropriate 4,5-dimethoxy substituted or 3,4,5-trimethoxy substituted 2-aminobenzamidine with the same 1,4-disubstituted piperazines. The products are known hypotensive agents.
    Type: Grant
    Filed: December 5, 1973
    Date of Patent: January 27, 1976
    Assignee: Pfizer Inc.
    Inventor: Hans-Jurgen E. Hess
  • 18.beta.-Glycyrrhetinic acid amides useful as antiulcer agents
    Patent number: 3934027
    Abstract: Amide derivatives of 18.beta.-glycyrrhetinic acid and its 3-alkanoyl derivatives useful as antiulcer agents wherein the amide is derived from an amino acid.
    Type: Grant
    Filed: June 24, 1974
    Date of Patent: January 20, 1976
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Roger P. Nelson
  • 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.ome ga.-pentanorprostaglandins
    Patent number: 3932389
    Abstract: The 2-descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorpr ostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: December 11, 1974
    Date of Patent: January 13, 1976
    Assignee: Pfizer Inc.
    Inventors: Michael R. Johnson, Thomas K. Schaaf, Jasjit S. Bindra, Hans-Jurgen E. Hess, James F. Eggler